Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc (NY: ZYME )

6.430 UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zymeworks Inc

< Previous 1 2 3 4 Next >
Zymeworks to Host First Quarter 2022 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
From Zymeworks Inc.
Via Business Wire
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Pricing of $100.0 Million Public Offering
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Proposed Public Offering
From Zymeworks Inc.
Via Business Wire
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
From Zymeworks Inc.
Via Business Wire
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
From Zymeworks Inc.
Via Business Wire
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
From Zymeworks Inc.
Via Business Wire
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
From Zymeworks Inc.
Via Business Wire
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
From Zymeworks Inc.
Via Business Wire
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
From Zymeworks Inc.
Via Business Wire
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
From Zymeworks Inc.
Via Business Wire
Zymeworks to Present at Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Zymeworks Reports 2021 Third Quarter Financial Results
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
From Zymeworks Inc.
Via Business Wire
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
From Zymeworks Inc.
Via Business Wire
Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress
From Zymeworks Inc.
Via Business Wire
Zymeworks Reports 2021 Second Quarter Financial Results
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks’ Azymetric™ and EFECT™ Therapeutic Platforms
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy
From Zymeworks Inc.
Via Business Wire
Zymeworks to Present at Ladenburg Thalmann Healthcare Conference
From Zymeworks Inc.
Via Business Wire
Zymeworks to Present at Jefferies Virtual Healthcare Conference
From Zymeworks Inc.
Via Business Wire
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
From Zymeworks Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.